Journal Title
Title of Journal:
|
|
|
Publisher
Springer, London
|
|
|
|
|
|
Authors: Matti S Aapro
Publish Date: 2013
Volume: , Issue: , Pages: 365-380
Abstract
Chemotherapyinduced febrile neutropenia FN may lead to dose reductions and/or delays that may decrease the chances of curative or lifeprolonging treatment and is related to increased patient mortality While often associated with a need for hospitalization this complication can also be treated in an outpatient setting in lowrisk patients Prophylactic treatment with granulocyte colonystimulating factors GCSFs such as filgrastim including approved biosimilars lenograstim or pegfilgrastim is available to reduce the risk of chemotherapyinduced neutropenia and its consequences according to the European Organisation for Research and Treatment of Cancer EORTC and other guidelines Prophylactic GCSF is recommended in patients receiving a chemotherapy regimen with a risk of FN above 20 Patientrelated risk factors in particular elderly age ≥65 years may increase the overall risk of FN and need to be evaluated to decide the use of prophylaxis for regimens with intermediate 10–20 risk of FN
Keywords:
.
|
Other Papers In This Journal:
|